Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03102021 · ClinicalTrials.gov registry record · Phase 2
The Effect of Human Recombinant Erythropoietin in Acute Renal Failure
A Phase 2 study, sponsored by North Texas Veterans Healthcare System.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT03102021 is a Phase 2 study that has completed, run by North Texas Veterans Healthcare System. The registered enrollment target is 25 participants.
The verdict
NCT03102021, a Phase 2 study, has completed, sponsored by North Texas Veterans Healthcare System.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if the use of erythropoietin when used in high dose during acute kidney injury can decrease the number of days of kidney injury.
Interventions
- DRUG saline
- DRUG erythropoietin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2006-03 |
| Est. Completion | 2013-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03102021
The ClinicalTrials.gov registry entry for NCT03102021 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is North Texas Veterans Healthcare System, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which saline is the first listed.
NCT03102021 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03102021 about?
NCT03102021 is a clinical study titled "The Effect of Human Recombinant Erythropoietin in Acute Renal Failure". The purpose of this study is to determine if the use of erythropoietin when used in high dose during acute kidney injury can decrease the number of days of kidney injury.
What is the current status of trial NCT03102021?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2006-03. Estimated completion is 2013-06.
What interventions are being tested in trial NCT03102021?
The interventions under investigation include: saline (DRUG), erythropoietin (DRUG).
Who is sponsoring clinical trial NCT03102021?
This trial is sponsored by North Texas Veterans Healthcare System, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.